| Literature DB >> 29339360 |
.
Abstract
The FDA has approved F1CDx, a comprehensive companion diagnostic test that can detect genetic alterations and two genomic signatures in any type of solid tumor. Patients with five common types of advanced cancer can be matched to one of 17 targeted therapies with this single test. ©2018 American Association for Cancer Research.Entities:
Year: 2018 PMID： 29339360 DOI： 10.1158/2159-8290.CD-NB2017-182
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397